![](https://poseida.com/wp-content/uploads/2023/04/news-watermark.png)
![](https://poseida.com/wp-content/uploads/2023/04/news-watermark-mobile.png)
NEWS CENTER
Poseida News Center
Featured Content
Read media coverage on Poseida, find resources for the working press, and get insights from our executive leadership team on how Poseida is advancing a new class of cell and gene therapies.
Poseida in the News
Eight companies tackling cancer with allogeneic cell therapy in 2024
|
June 13, 2024
Top 10 Publicly Owned Gene Editing Therapy Companies
|
May 31, 2024
Astellas taps Poseida for second CAR-T deal focused on solid tumors
|
May 1, 2024
Astellas hitches a ride in Poseida’s convertible for $50M cell therapy collaboration
|
May 1, 2024
AACR: To bring CAR-T to solid tumors, Poseida thinks we need to boost conditioning therapy
|
April 10, 2024
FDA Grants Orphan Drug Designation to P-BCMA-ALLO1 in R/R Multiple Myeloma
|
March 14, 2024
A Significant Milestone for the Future of Gene Editing
|
February 28, 2024
Poseida: New CEO, same passion for allogeneic therapies
|
February 26, 2024
![](https://poseida.com/wp-content/uploads/2023/04/5-layers-2-1.png)
![](https://poseida.com/wp-content/uploads/2023/04/5-layers-3.png)
Executive Perspectives
Press Releases
Poseida Therapeutics Announces Participation in Stifel’s 2024 Virtual Cell Therapy Forum
|
July 1, 2024
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
|
June 3, 2024
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
|
May 14, 2024
Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting
|
May 9, 2024
![](https://poseida.com/wp-content/uploads/2023/04/6-layers-2.png)
![](https://poseida.com/wp-content/uploads/2023/04/6-layers-3.png)
Media Library
Usage rights & restrictions:
These media assets are free for editorial broadcast, print, online and radio use. They are restricted for other purposes.